Key result
Planned translational study investigates β1-adrenergic receptor desensitization in HF to identify sex-specific therapeutic targets.
Why the study?
It remains unclear whether reduced myocardial beta1-adrenergic receptor density in heart failure causes dysfunction or represents an epiphenomenon, and whether novel sex-specific pathways and peripheral biomarkers can be identified.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications; leaves open sex-specific β1-AR targets in heart failure.
Background: This study is part of the HEAL ITALIA partnership, funded by the National Recovery and Resilience Plan (PNRR) and the European Union. Heart failure (HF) is a serious health problem, with a reduced density of the β1-adrenergic receptor (β1-AR) in the myocardium as a hallmark. It is unclear whether this downregulation causes dysfunction or represents an epiphenomenon. Recent evidence implicates oxidative stress and mitochondrial signaling, particularly through the 18 kDa translocator protein (TSPO), in the regulation of the β1-AR, with possible modulation by estrogen. Objectives: To determine (1) the role of β1-AR desensitization in the onset and development of HF; (2) whether monocytes can represent a suitable ex vivo model for sex-oriented mechanistic studies in the cardiac field; (3) whether monocytes isolated from peripheral blood of patients can represent a diagnostic and/or therapy response biomarker by monitoring β1-AR density; (4) whether and how the mitochondrial receptor TSPO is involved in the β1-AR dysregulation observed in HF; and (5) whether the mechanisms linked to the onset of HF are regulated in a sex-specific manner through the effect of estrogen and/or the X chromosome on the expression of specific microRNAs. Methods: Using an integrated in vitro-ex vivo-in vivo methodological approach, we will evaluate the density of β1/β2-AR receptors, the downstream signaling (GRK2/β-arrestin), mitochondrial and redox parameters, and miRNA profiles in human monocytes and cardiomyocytes, and in mouse hearts after HF following pressure overload. Conclusions: The goal is to better understand the mechanisms underlying β1-AR desensitization, verify monocytes as peripheral markers of disease progression and response to therapy, and provide potentially useful information for the development of gender-specific therapies for heart failure.
No takes yet. Share an insight, caveat, or question.
Vona et al. (2026) studied Heart failure. This planned translational study aims to investigate the mechanisms of β1-adrenergic receptor desensitization in heart failure to identify sex-specific biomarkers and therapeutic targets.
Synapse has enriched 10 related papers. Consider them for comparative context: